The Endocannabinoid System and Parkinson Disease

Andrea Giuffrida; Alex Martinez

doi:10.1016/B978-0-12-809666-6.00003-4

The Endocannabinoid System and Parkinson Disease

Andrea Giuffrida, Alex Martinez

Department of Pharmacology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

8 Scopus citations

Abstract

Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

Original language	English (US)
Title of host publication	The Endocannabinoid System
Subtitle of host publication	Genetics, Biochemistry, Brain Disorders, and Therapy
Publisher	Elsevier Inc.
Pages	63-81
Number of pages	19
ISBN (Electronic)	9780128096673
ISBN (Print)	9780128096666
DOIs	https://doi.org/10.1016/B978-0-12-809666-6.00003-4
State	Published - May 16 2017

Keywords

Basal ganglia
Cannabinoid receptors
Endocannabinoids
L-DOPA-induced dyskinesia
Neurodegeneration

ASJC Scopus subject areas

General Agricultural and Biological Sciences

Access to Document

10.1016/B978-0-12-809666-6.00003-4

Cite this

@inbook{9ae06d4d1d35420fba381c8aa7a6097b,

title = "The Endocannabinoid System and Parkinson Disease",

abstract = "Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.",

keywords = "Basal ganglia, Cannabinoid receptors, Endocannabinoids, L-DOPA-induced dyskinesia, Neurodegeneration",

author = "Andrea Giuffrida and Alex Martinez",

year = "2017",

month = may,

day = "16",

doi = "10.1016/B978-0-12-809666-6.00003-4",

language = "English (US)",

isbn = "9780128096666",

pages = "63--81",

booktitle = "The Endocannabinoid System",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Endocannabinoid System and Parkinson Disease

AU - Giuffrida, Andrea

AU - Martinez, Alex

PY - 2017/5/16

Y1 - 2017/5/16

N2 - Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

AB - Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

KW - Basal ganglia

KW - Cannabinoid receptors

KW - Endocannabinoids

KW - L-DOPA-induced dyskinesia

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=85041206035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041206035&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-809666-6.00003-4

DO - 10.1016/B978-0-12-809666-6.00003-4

M3 - Chapter

AN - SCOPUS:85041206035

SN - 9780128096666

SP - 63

EP - 81

BT - The Endocannabinoid System

PB - Elsevier Inc.

ER -

The Endocannabinoid System and Parkinson Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this